Arie Pieter Kappetein

List of Publications by Year in Descending Order

314 papers	35,823 citations	78 h-index	187 g-index
342 ext. papers	42,592 ext. citations	6.5 avg, IF	6.6 L-index

#	Paper	IF	Citations
314	White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial. *Coronary Artery Disease*, **2022**, 31, 45-51	1.4	
313	Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease. *Coronary Artery Disease*, **2022**, 31, 37-44	1.4	0
312	Impact of lesion preparation strategies on outcomes of left main PCI: The EXCEL trial. *Catheterization and Cardiovascular Interventions*, **2021**, 98, 24-32	2.7	3
311	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization in Patients With Heavy Calcification.. *JACC: Cardiovascular Interventions*, **2021**, 15, 193-193	5	1
310	Geographical variations in left main coronary artery revascularisation: a pre-specified analysis of the EXCEL trial. *EuroIntervention*, **2021**,	3.1	1
309	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. *Lancet, The*, **2021**,	40	17
308	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). *American Journal of Cardiology*, **2021**, 143, 21-28	3	
307	Impact of stent length and diameter on 10-year mortality in the SYNTAXES trial. *Catheterization and Cardiovascular Interventions*, **2021**, 98, E379-E387	2.7	1
306	Impact of the CABG SYNTAX score on all-cause death at 10 years: a SYNTAX Extended Survival (SYNTAXES) substudy. *EuroIntervention*, **2021**, 17, 75-77	3.1	
305	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. *Journal of the American College of Cardiology*, **2021**, 77, 2761-2773	15.1	8
304	Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). *American Journal of Cardiology*, **2021**, 151, 30-38	3	1
303	Transit time flow measurement of coronary bypass grafts before and after protamine administration. *Journal of Cardiothoracic Surgery*, **2021**, 16, 195	1.6	2
302	Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. *Journal of the American College of Cardiology*, **2021**, 78, 27-38	15.1	12
301	Essential information on surgical heart valve characteristics for optimal valve prosthesis selection: Expert consensus document from the European Association for Cardio-Thoracic Surgery (EACTS)-The Society of Thoracic Surgeons (STS)-American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. *Journal of Thoracic and Cardiovascular Surgery*, **2021**, 161, 545-558	1.5	3
300	Essential Information on Surgical Heart Valve Characteristics for Optimal Valve Prosthesis Selection: Expert Consensus Document From the European Association for Cardio-Thoracic Surgery (EACTS)-The Society of Thoracic Surgeons (STS)-American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. *Annals of Thoracic Surgery*, **2021**, 111, 314-326	2.7	0
299	Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions. *Journal of the American College of Cardiology*, **2021**, 77, 529-540	15.1	10
298	Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. *European Journal of Cardio-thoracic Surgery*, **2021**,	3	2

297	Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. *Clinical Research in Cardiology*, **2021**, 110, 1543-1553	6.1	0
296	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. *Clinical Research in Cardiology*, **2021**, 110, 1083-1095	6.1	1
295	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. *Circulation*, **2021**, 144, 96-109	16.7	11
294	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. *European Heart Journal*, **2021**,	9.5	2
293	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. *Clinical Research in Cardiology*, **2021**, 110, 1680-1691	6.1	0
292	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. *European Heart Journal*, **2021**,	9.5	4
291	Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease. *International Journal of Cardiology*, **2021**, 341, 9-12	3.2	0
290	Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. *EuroIntervention*, **2021**,	3.1	1
289	Natural History of Asymptomatic Severe Aortic Stenosis and the Association of Early Intervention With Outcomes: A Systematic Review and Meta-analysis. *JAMA Cardiology*, **2020**, 5, 1102-1112	16.2	12
288	Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 323-331	5	11
287	Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. *European Journal of Heart Failure*, **2020**, 22, 871-879	12.3	9
286	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial. *JACC: Cardiovascular Interventions*, **2020**, 13, 375-387	5	26
285	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. *American Journal of Cardiology*, **2020**, 127, 16-24	3	1
284	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. *European Journal of Cardio-thoracic Surgery*, **2020**, 57, 676-683	3	7
283	Computed Tomography Annular Dimensions: A Novel Method to Compare Prosthetic Valve Hemodynamics. *Annals of Thoracic Surgery*, **2020**, 110, 1502-1510	2.7	1
282	Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization. *Journal of the American College of Cardiology*, **2020**, 76, 889-899	15.1	13
281	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. *Lancet, The*, **2020**, 396, 1399-1412	40	39
280	Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. *Journal of the American College of Cardiology*, **2020**, 76, 1622-1639	15.1	25

279	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. *Journal of the American College of Cardiology*, **2020**, 76, 1609-1621	15.1	26
278	Sutureless versus Stented Bioprostheses for Aortic Valve Replacement: The Randomized PERSIST-AVR Study Design. *Thoracic and Cardiovascular Surgeon*, **2020**, 68, 114-123	1.6	11
277	Intraoperative transit-time flow measurement and high-frequency ultrasound assessment in coronary artery bypass grafting. *Journal of Thoracic and Cardiovascular Surgery*, **2020**, 159, 1283-1292.e2	1.5	21
276	The fallacy of indexed effective orifice area charts to predict prosthesis-patient mismatch after prosthesis implantation. *European Heart Journal Cardiovascular Imaging*, **2020**, 21, 1116-1122	4.1	8
275	Considerations for an optimal definition of procedural myocardial infarction. *European Heart Journal*, **2020**, 41, 1704-1705	9.5	5
274	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. *Lancet, The*, **2019**, 394, 1325-1334	40	206
273	Left Main Coronary Artery Disease Revascularization According to the SYNTAX Score. *Circulation: Cardiovascular Interventions*, **2019**, 12, e008007	6	12
272	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. *New England Journal of Medicine*, **2019**, 381, 1820-1830	59.2	265
271	Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial. *JAMA Cardiology*, **2019**, 4, 810-814	16.2	7
270	Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial. *American Heart Journal*, **2019**, 214, 9-17	4.9	4
269	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. *Journal of the American College of Cardiology*, **2019**, 73, 1877-1886	15.1	21
268	Improving coronary artery bypass grafting: a systematic review and meta-analysis on the impact of adopting transit-time flow measurement. *European Journal of Cardio-thoracic Surgery*, **2019**, 56, 654-663	3	30
267	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. *European Heart Journal*, **2019**, 40, 1930-1941	9.5	40
266	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. *Journal of the American College of Cardiology*, **2019**, 73, 1616-1628	15.1	37
265	Computed Tomography-Based Indexed Aortic Annulus Size to Predict Prosthesis-Patient Mismatch. *Circulation: Cardiovascular Interventions*, **2019**, 12, e007396	6	6
264	Heart Team decision making and long-term outcomes for 1000 consecutive cases of coronary artery disease. *Interactive Cardiovascular and Thoracic Surgery*, **2019**, 28, 206-213	1.8	15
263	Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary Artery Disease. *Journal of the American College of Cardiology*, **2019**, 74, 729-740	15.1	8
262	Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial. *EuroIntervention*, **2019**, 15, e531-e538	3.1	0

261	Causes of death in intermediate-risk patients: The Randomized Surgical Replacement and Transcatheter Aortic Valve Implantation Trial. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 158, 718-728.e3	1.5	10
260	Life-long clinical outcome after the first myocardial revascularization procedures: 40-year follow-up after coronary artery bypass grafting and percutaneous coronary intervention in Rotterdam. *Interactive Cardiovascular and Thoracic Surgery*, **2019**, 28, 852-859	1.8	5
259	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease: analysis from the EXCEL trial. *Coronary Artery Disease*, **2019**, 30, 143-149	1.4	1
258	Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trial *European Journal of Cardio-thoracic Surgery*, **2019**, 55, 501-510	3	10
257	Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial. *European Journal of Cardio-thoracic Surgery*, **2019**, 55, 1144-1151	3	4
256	C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. *American Heart Journal*, **2019**, 210, 49-57	4.9	9
255	Antithrombotic therapy and bleeding events after aortic valve replacement with a novel bioprosthesis. *Journal of Thoracic and Cardiovascular Surgery*, **2019**,	1.5	3
254	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. *Lancet, The*, **2018**, 391, 939-948	40	290
253	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. *Circulation*, **2018**, 138, 469-478	16.7	14
252	Compliance With Guideline-Directed Medical Therapy in Contemporary Coronary Revascularization Trials. *Journal of the American College of Cardiology*, **2018**, 71, 591-602	15.1	54
251	New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease: The EXCEL Trial. *Journal of the American College of Cardiology*, **2018**, 71, 739-748	15.1	65
250	Standardized Definition of Structural Valve Degeneration for Surgical and Transcatheter Bioprosthetic Aortic Valves. *Circulation*, **2018**, 137, 388-399	16.7	194
249	Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. *European Heart Journal*, **2018**, 39, 2635-2642	9.5	134
248	A case-vignette based assessment of patient perspective on coronary revascularization strategies, the OPINION study. *Journal of Cardiology*, **2018**, 72, 149-154	3	5
247	Long-term outlook for transcatheter aortic valve replacement. *Trends in Cardiovascular Medicine*, **2018**, 28, 174-183	6.9	10
246	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. *Journal of the American College of Cardiology*, **2018**, 72, 754-765	15.1	39
245	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. *Journal of the American College of Cardiology*, **2018**, 72, 386-398	15.1	59
244	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. *Circulation*, **2018**, 137, 2635-2650	16.7	172

243	Reply to Gasz. *European Journal of Cardio-thoracic Surgery*, **2018**, 54, 196-197	3	
242	One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. *EuroIntervention*, **2018**, 14, 877-883	3.1	45
241	Mechanical Complications of Acute Myocardial Infarction **2018**, 341-357		
240	Recognition, assessment and management of the mechanical complications of acute myocardial infarction. *Heart*, **2018**, 104, 1216-1223	5.1	19
239	Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease: Results From the EXCEL Trial. *JACC: Cardiovascular Interventions*, **2018**, 11, 2441-2450	5	4
238	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. *Circulation: Cardiovascular Interventions*, **2018**, 11, e007007	6	24
237	Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients. *Journal of the American College of Cardiology*, **2018**, 72, 2109-2119	15.1	20
236	Interpretation of results of pooled analysis of individual patient data - AuthorsQreply. *Lancet, The*, **2018**, 392, 818	40	4
235	One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 156, 1368-1377.e5	1.5	19
234	Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site: Results From the EXCEL Trial. *JACC: Cardiovascular Interventions*, **2018**, 11, 1224-1233	5	29
233	Outcomes After Coronary Stenting or Bypass Surgery for Men and Women With Unprotected Left Main Disease: The EXCEL Trial. *JACC: Cardiovascular Interventions*, **2018**, 11, 1234-1243	5	42
232	Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. *Journal of the American College of Cardiology*, **2017**, 69, 2039-2050	15.1	39
231	Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 425-431	3	18
230	Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 14-25	3	77
229	Mechanical versus bioprosthetic aortic valve replacement. *European Heart Journal*, **2017**, 38, 2183-2191	9.5	136
228	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 206-217	3	23
227	Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass grafting. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 445-453	3	14
226	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. *American Heart Journal*, **2017**, 190, 54-63	4.9	62

225	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Disease. *New England Journal of Medicine*, **2017**, 376, 1089	59.2	8
224	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease: Results From the EXCEL Trial. *Journal of the American College of Cardiology*, **2017**, 70, 3113-3122	15.1	41
223	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. *European Heart Journal*, **2017**, 38, 3124-3134	9.5	165
222	Approaches to the Role of The Heart Team in Therapeutic Decision Making for Heart Valve Disease. *Structural Heart*, **2017**, 1, 249-255	0.6	8
221	Standards defining a Heart Valve Centre: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. *European Journal of Cardio-thoracic Surgery*, **2017**, 52, 418-424	3	8
220	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the	9.5	198
219	Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery	3	88
218	Standards defining a Heart Valve Centre: ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. *European Heart Journal*, **2017**, 38, 2177-2183	9.5	53
217	Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. *Structural Heart*, **2017**, 1, 267-274	0.6	3
216	EACTS clinical statement: guidance for the provision of adult cardiac surgery. *European Journal of Cardio-thoracic Surgery*, **2016**, 50, 1006-1009	3	16
215	Transcatheter Lotus Valve Implantation in a Stenotic Mitral Valve. *JACC: Cardiovascular Interventions*, **2016**, 9, e215-e217	5	5
214	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. *New England Journal of Medicine*, **2016**, 375, 2223-2235	59.2	603
213	Transcatheter Mitral Valve Implantation in a Patient With an Aortic Mechanical Valve. *JACC: Cardiovascular Interventions*, **2016**, 9, e31-e33	5	1
212	Causes of Death Following PCI Versus CABG in Complex CAD: 5-Year Follow-Up of SYNTAX. *Journal of the American College of Cardiology*, **2016**, 67, 42-55	15.1	70
211	Revascularization Options: Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention. *Heart Failure Clinics*, **2016**, 12, 135-9	3.3	9
210	Coronary artery disease: a dam in the river for ranolazine. *Lancet, The*, **2016**, 387, 100-2	40	1
209	Current decision making and short-term outcome in patients with degenerative aortic stenosis: the Pooled-RotterdAm-Milano-Toulouse In Collaboration Aortic Stenosis survey. *EuroIntervention*, **2016**, 11, e1305-13	3.1	15
208	Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. *EuroIntervention*, **2016**, 12, 775-82	3.1	19

207	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. *EuroIntervention*, **2016**, 12, 861-72	3.1	51
206	Conceptual model for early health technology assessment of current and novel heart valve interventions. *Open Heart*, **2016**, 3, e000500	3	15
205	Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval. *Circulation*, **2016**, 133, 2086-93	16.7	8
204	The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. *Annals of Thoracic Surgery*, **2016**, 101, 801-9	2.7	198
203	Rationale and design of the Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with ADvanced heart failure (TAVR UNLOAD) trial. *American Heart Journal*, **2016**, 182, 80-88	4.9	83
202	Diagnosis and management of aortic valve stenosis in patients with heart failure. *European Journal of Heart Failure*, **2016**, 18, 469-81	12.3	15
201	Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry. *European Journal of Cardio-thoracic Surgery*, **2015**, 47, 685-95	3	21
200	Optimal medical therapy improves clinical outcomes in patients undergoing revascularization with percutaneous coronary intervention or coronary artery bypass grafting: insights from the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial at	16.7	122
199	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part´1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. *Journal of the American College of Cardiology*, **2015**, 66, 278-307	15.1	128
198	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part´2: Endpoint Definitions: A Consensus Document From the Mitral Valve Academic Research Consortium. *Journal of the American College of Cardiology*, **2015**, 66, 308-321	15.1	268
197	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. *European Heart Journal*, **2015**, 36, 1851-77	9.5	26
196	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium. *European Heart Journal*, **2015**, 36, 1878-91	9.5	70
195	Incidence and predictors of debris embolizing to the brain during transcatheter aortic valve implantation. *JACC: Cardiovascular Interventions*, **2015**, 8, 718-24	5	120
194	Validation of the SYNTAX revascularization index to quantify reasonable level of incomplete revascularization after percutaneous coronary intervention. *American Journal of Cardiology*, **2015**, 116, 174-86	3	22
193	Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. *Journal of the American College of Cardiology*, **2015**, 65, 1107-15	15.1	80
192	50th Anniversary Landmark Commentary on Carpentier A, Guermonprez JL, Deloche A, Frechette C, DuBost C. The aorta-to-coronary radial artery bypass graft. Ann Thorac Surg 1973;16:111-21. *Annals of Thoracic Surgery*, **2015**, 99, 1500	2.7	0
191	Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. *European Journal of Cardio-thoracic Surgery*, **2015**, 48, 809-16	3	2
190	Percutaneous coronary invervention versus coronary artery bypass grafting: a meta-analysis. *Journal of Thoracic and Cardiovascular Surgery*, **2015**, 149, 831-8.e1-13	1.5	24

189	A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users. *Genetics in Medicine*, **2015**, 17, 3-11	8.1	35
188	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: an analysis of the SYNTAX study. *Catheterization and Cardiovascular Interventions*, **2015**, 85, 199-206	2.7	20
187	Reply to Hern□dez-Vaquero et al. *European Journal of Cardio-thoracic Surgery*, **2015**, 48, 177-8	3	
186	The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. *Journal of Thoracic and Cardiovascular Surgery*, **2015**, 150, 597-606.e2	1.5	11
185	Age cutoffs for bioprosthetic vs mechanical aortic valve replacement. *JAMA - Journal of the American Medical Association*, **2015**, 313, 522-3	27.4	1
184	Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective. *Heart*, **2015**, 101, 1980-8	5.1	11
183	What the cardiothoracic surgeon wants to know from the radiologist: from X-ray reporting to imaging consultancy and Heart Team membership. *Pediatric Radiology*, **2015**, 45, 27-31	2.8	0
182	Transcatheter lotus valve implantation in a degenerated carpentier-edwards bioprosthesis. *JACC: Cardiovascular Interventions*, **2015**, 8, e27-e28	5	1
181	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. *European Heart Journal*, **2015**, 36, 1231-41	9.5	79
180	CABG, stents, or hybrid procedures for left main disease?. *EuroIntervention*, **2015**, 11 Suppl V, V111-4	3.1	7
179	Transcatheter Lotus valve implantation in a regurgitant SAPIEN 3 valve. *EuroIntervention*, **2015**, 11, 356	3.1	6
178	Measuring risk in valvular interventions: from low risk to futility. *EuroIntervention*, **2015**, 11 Suppl W, W23-5	3.1	
177	The SYNTAX score and its clinical implications. *Heart*, **2014**, 100, 169-77	5.1	47
176	Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. *European Heart Journal*, **2014**, 35, 2821-30	9.5	222
175	Cost, quality, and value in coronary artery bypass grafting. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 148, 2729-35.e1	1.5	16
174	Revascularization options: coronary artery bypass surgery and percutaneous coronary intervention. *Cardiology Clinics*, **2014**, 32, 457-61	2.5	6
173	Widening clinical applications of the SYNTAX Score. *Heart*, **2014**, 100, 276-87	5.1	48
172	2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Heart Journal*, **2014**, 35, 2541-619	9.5	3467

171	Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation*, **2014**, 130, 1146-57	16.7	64
170	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. *BMJ, The*, **2014**, 348, g3859	5.9	210
169	Prediction of costs and length of stay in coronary artery bypass grafting. *Annals of Thoracic Surgery*, **2014**, 98, 1286-93	2.7	45
168	Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial. *Circulation*, **2014**, 129, 2388-94	16.7	320
167	Invited commentary. *Annals of Thoracic Surgery*, **2014**, 97, 528-9	2.7	
166	Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. *European Journal of Cardio-thoracic Surgery*, **2014**, 46, 400-8; discussion 408	3	75
165	Response to letter regarding article, "Quantification of incomplete revascularization and its association with five-year mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial: validation of the residual SYNTAX Score". *Circulation*, **2014**, 129, e355-6	16.7	1
164	Cause of death after transcatheter aortic valve implantation. *Catheterization and Cardiovascular Interventions*, **2014**, 83, E277-82	2.7	36
163	Role of percutaneous coronary intervention in the treatment of left main coronary artery disease. *Seminars in Thoracic and Cardiovascular Surgery*, **2014**, 26, 187-91	1.7	
162	2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Journal of*	3	588
161	Transapical versus transfemoral aortic valve implantation: a multicenter collaborative study. *Annals of Thoracic Surgery*, **2014**, 97, 22-8	2.7	57
160	Adoption of Transcatheter Aortic Valve Implantation in Western Europe. *Interventional Cardiology Review*, **2014**, 9, 37-40	4.2	6
159	Patient selection for TAVI in 2014: is there a justification for treating low- or intermediate-risk patients? The surgeon's view. *EuroIntervention*, **2014**, 10 Suppl U, U11-5	3.1	8
158	Transcatheter aortic valve replacement and vascular complications definitions. *EuroIntervention*, **2014**, 9, 1317-22	3.1	13
157	Multivessel coronary artery disease: quantifying how recent trials should influence clinical practice. *Expert Review of Cardiovascular Therapy*, **2013**, 11, 903-18	2.5	6
156	Prediction of 1-year mortality in patients with acute coronary syndromes undergoing percutaneous coronary intervention: validation of the logistic clinical SYNTAX (Synergy Between Percutaneous Coronary Interventions With Taxus and Cardiac Surgery) score. *JACC: Cardiovascular Interventions*, **2013**, 6, 737-45	5	42
155	Costs for surgical aortic valve replacement according to preoperative risk categories. *Annals of Thoracic Surgery*, **2013**, 96, 500-6	2.7	45
154	CABG or PCI for revascularisation in patients with diabetes?. *Lancet Diabetes and Endocrinology,the*, **2013**, 1, 266-8	18.1	5

153	Short-term and long-term clinical impact of stent thrombosis and graft occlusion in the SYNTAX trial at 5 years: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery trial. *Journal of the American College of Cardiology*, **2013**, 62, 2360-2369	15.1	47
152	Coronary artery bypass grafting: Part 2--optimizing outcomes and future prospects. *European Heart Journal*, **2013**, 34, 2873-86	9.5	83
151	Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet, The*, **2013**, 381, 629-38	40	1109
150	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 145, 6-23	1.5	647
149	Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. *Journal of the American College of Cardiology*, **2013**, 61, 1125-36	15.1	294
148	Analysis of stroke occurring in the SYNTAX trial comparing coronary artery bypass surgery and percutaneous coronary intervention in the treatment of complex coronary artery disease. *JACC: Cardiovascular Interventions*, **2013**, 6, 344-54	5	36
147	Incidence, correlates, and significance of abnormal cardiac enzyme rises in patients treated with surgical or percutaneous based revascularisation: a substudy from the Synergy between Percutaneous Coronary Interventions with Taxus and Cardiac Surgery (SYNTAX) Trial. *International Journal of Cardiology*, **2013**, 168, 5287-92	3.2	13
146	Complete revascularization is not a prerequisite for success in current transcatheter aortic valve implantation practice. *JACC: Cardiovascular Interventions*, **2013**, 6, 867-75	5	89
145	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). *Revista Espanola De Cardiologia*, **2013**, 66, 131.e1-131.e42	1.5	
144	Transcatheter aortic valve replacement in Europe: adoption trends and factors influencing device utilization. *Journal of the American College of Cardiology*, **2013**, 62, 210-219	15.1	159
143	Impact of methodology and assumptions in a cost-effectiveness analysis on transcatheter aortic valve replacement. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 145, 607	1.5	1
142	Long-term survival of young patients with coronary artery disease is best realized through surgical revascularization with mammary arteries. *Journal of the American College of Cardiology*, **2013**, 61, 2312-3	15.1	1
141	A 3-center comparison of 1-year mortality outcomes between transcatheter aortic valve implantation and surgical aortic valve replacement on the basis of propensity score matching among intermediate-risk surgical patients. *JACC: Cardiovascular Interventions*, **2013**, 6, 443-51	5	160
140	The negative impact of incomplete angiographic revascularization on clinical outcomes and its association with total occlusions: the SYNTAX (Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial. *Journal of the American College of Cardiology*,	15.1	199
139	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. *Lancet, The*, **2013**, 381, 639-50	40	507
138	A systematic review of risk prediction in adult cardiac surgery: considerations for future model development. *European Journal of Cardio-thoracic Surgery*, **2013**, 43, e121-9	3	34
137	The rationale for Heart Team decision-making for patients with stable, complex coronary artery disease. *European Heart Journal*, **2013**, 34, 2510-8	9.5	130
136	Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. *Journal of the American College of Cardiology*, **2013**, 62, 1002-12	15.1	597

135	Coronary artery bypass grafting: Part 1--the evolution over the first 50 years. *European Heart Journal*, **2013**, 34, 2862-72	9.5	90
134	The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. *European Journal of Cardio-thoracic Surgery*, **2013**, 44, 1006-11; discussion 1011	3	48
133	The European Association for Cardio-Thoracic Surgery (EACTS) database: an introduction. *European Journal of Cardio-thoracic Surgery*, **2013**, 44, e175-80	3	29
132	Arterial grafting and complete revascularization: challenge or compromise?. *Current Opinion in Cardiology*, **2013**, 28, 646-53	2.1	5
131	Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. *European Journal of Cardio-thoracic Surgery*, **2013**, 43, 1006-13	3	243
130	Single-centre experience with mitral valve repair in asymptomatic patients with severe mitral valve regurgitation. *Interactive Cardiovascular and Thoracic Surgery*, **2013**, 16, 731-7	1.8	4
129	Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. *Circulation*, **2013**, 128, 141-51	16.7	247
128	Subgroup analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass surgery. *JAMA - Journal of the American Medical Association*, **2013**, 310, 2097-8	27.4	13
127	Minimally invasive transaortic transcatheter aortic valve implantation of the CoreValve prosthesis: the direct aortic approach through a mini-sternotomy. *Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery*, **2013**, 2013, mmt018	0.2	3
126	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. *EuroIntervention*, **2013**, 8, 1277-85	3.1	53
125	The coronary artery bypass graft SYNTAX Score: final five-year outcomes from the SYNTAX-LE MANS left main angiographic substudy. *EuroIntervention*, **2013**, 9, 1009-10	3.1	11
124	Cost-effectiveness of transcatheter valvular interventions: economic challenges. *EuroIntervention*, **2013**, 9 Suppl, S48-54	3.1	16
123	Failing surgical bioprosthesis in aortic and mitral position. *EuroIntervention*, **2013**, 9 Suppl, S77-83	3.1	3
122	Invited commentary. *Annals of Thoracic Surgery*, **2012**, 93, 530	2.7	
121	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Annals of Thoracic Surgery*, **2012**, 93, 1494-516	2.7	47
120	Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. *Catheterization and Cardiovascular Interventions*, **2012**, 79, 198-209	2.7	40
119	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. *Journal of the American College of Cardiology*, **2012**, 59, 1200-54	15.1	580
118	Persistent annual permanent pacemaker implantation rate after surgical aortic valve replacement in patients with severe aortic stenosis. *Annals of Thoracic Surgery*, **2012**, 94, 1143-9	2.7	41

117	Costs of transcatheter versus surgical aortic valve replacement in intermediate-risk patients. *Annals of Thoracic Surgery*, **2012**, 94, 1954-60	2.7	75
116	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular	1.5	93
115	Guidelines on the management of valvular heart disease (version 2012). *European Heart Journal*, **2012**, 33, 2451-96	9.5	2866
114	Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *European Journal of Cardio-thoracic Surgery*, **2012**, 42, S1-44	3	1002
113	A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). *American Heart Journal*, **2012**, 163, 931-937.e1	4.9	139
112	Drug-eluting stent implantation for coronary artery disease: current stents and a comparison with bypass surgery. *Current Opinion in Pharmacology*, **2012**, 12, 147-54	5.1	3
111	Transcatheter aortic valve implantation: 10-year anniversary part II: clinical implications. *European Heart Journal*, **2012**, 33, 2399-402	9.5	41
110	Non-inferiority study design: lessons to be learned from cardiovascular trials. *European Heart Journal*, **2012**, 33, 1318-24	9.5	96
109	Transcatheter aortic valve implantation 10-year anniversary: review of current evidence and clinical implications. *European Heart Journal*, **2012**, 33, 2388-98	9.5	109
108	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. *European Heart Journal*, **2012**, 33, 3098-104	9.5	113
107	Appropriate coronary artery bypass grafting use in the percutaneous coronary intervention era: are we finally making progress?. *Seminars in Thoracic and Cardiovascular Surgery*, **2012**, 24, 241-3	1.7	2
106	Clinical outcomes after transcatheter aortic valve replacement using valve academic research consortium definitions: a weighted meta-analysis of 3,519 patients from 16 studies. *Journal of the American College of Cardiology*, **2012**, 59, 2317-26	15.1	435
105	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Journal of the American College of Cardiology*, **2012**, 60, 1438-54	15.1	1306
104	Risk profile and 3-year outcomes from the SYNTAX percutaneous coronary intervention and coronary artery bypass grafting nested registries. *JACC: Cardiovascular Interventions*, **2012**, 5, 618-25	5	64
103	A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. *JACC: Cardiovascular Interventions*, **2012**, 5, 606-17	5	76
102	Incidence, predictors and outcomes of incomplete revascularization after percutaneous coronary intervention and coronary artery bypass grafting: a subgroup analysis of 3-year SYNTAX data. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, 535-41	3	159
101	Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention?: implications for future treatment comparisons. *Circulation: Cardiovascular Quality and Outcomes*, **2012**, 5, 267-75	5.8	19
100	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collaboration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. *Catheterization and Cardiovascular Interventions*, **2012**, 79, 1023-82	2.7	16

99	Details in a meta-analysis comparing mitral valve repair to replacement for ischemic regurgitation. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, 236-7; author reply 237-8	3	2
98	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *European Heart Journal*, **2012**, 33, 2403-18	9.5	706
97	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). *European Journal of Cardio-thoracic Surgery*, **2012**, 42, S45-60	3	554
96	EACTS guidelines for the use of patient safety checklists. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, 993-1004	3	23
95	Preoperative and operative predictors of delirium after cardiac surgery in elderly patients. *European Journal of Cardio-thoracic Surgery*, **2012**, 41, 544-9	3	101
94	Towards excellence in revascularization for left main coronary artery disease. *Current Opinion in Cardiology*, **2012**, 27, 604-10	2.1	3
93	ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. *European Heart Journal*, **2012**, 33, 822-8, 828a, 828b	9.5	114
92	Off-pump or on-pump coronary-artery bypass grafting. *New England Journal of Medicine*, **2012**, 367, 577-8; author reply 578	59.2	9
91	The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. *European Heart Journal*, **2012**, 33, 1518-29	9.5	288
90	Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians". *Stroke*, **2012**, 43, e46-7; author reply e49	6.7	
89	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial. *European Heart Journal*, **2012**, 33, 3105-13	9.5	94
88	What do we know about the natural history of severe symptomatic aortic valve stenosis?. *Interventional Cardiology*, **2012**, 4, 203-210	3	
87	Completely percutaneous transcatheter aortic valve implantation through transaxillary route: an evolving concept. *EuroIntervention*, **2012**, 7, 1340-2	3.1	15
86	The SURTAVI model: proposal for a pragmatic risk stratification for patients with severe aortic stenosis. *EuroIntervention*, **2012**, 8, 258-66	3.1	43
85	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *EuroIntervention*, **2012**, 8, 782-95	3.1	149
84	Determinants of long-term outcome following bypass surgery **2012**, 422-427		
83	Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *Journal of the American College of Cardiology*, **2011**, 57, 253-69	15.1	662
82	Nonrandomized data on drug-eluting stents compared with coronary bypass surgery caution with interpretation. *Journal of the American College of Cardiology*, **2011**, 57, 2457-8; author reply 2458-9	15.1	1

81	Current concepts on coronary revascularization in diabetic patients. *European Heart Journal*, **2011**, 32, 2748-57	9.5	67
80	Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. *European Heart Journal*, **2011**, 32, 2125-34	9.5	417
79	A crucial factor in shared decision making: the team approach. *Lancet, The*, **2011**, 377, 1836	40	27
78	Surgery in current therapy for infective endocarditis. *Vascular Health and Risk Management*, **2011**, 7, 255-63	4.4	22
77	Complex coronary anatomy in coronary artery bypass graft surgery: impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years. *Journal of Thoracic and Cardiovascular Surgery*, **2011**, 141, 130-40	1.5	101
76	Methodologic issues regarding background mortality in observational studies. *Journal of Thoracic and Cardiovascular Surgery*, **2011**, 142, 1289-90; author reply 1290	1.5	2
75	Effect of experience on results of transcatheter aortic valve implantation using a Medtronic CoreValve System. *American Journal of Cardiology*, **2011**, 107, 1824-9	3	45
74	Bypass versus drug-eluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. *Annals of Thoracic Surgery*, **2011**, 92, 2140-6	2.7	71
73	In-hospital complications after transcatheter aortic valve implantation revisited according to the Valve Academic Research Consortium definitions. *Catheterization and Cardiovascular Interventions*, **2011**, 78, 457-67	2.7	46
72	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. *European Heart Journal*, **2011**, 32, 205-17	9.5	510
71	Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel. *JAMA - Journal of the American Medical Association*, **2011**, 305, 467-8; author reply 468	27.4	2
70	Quality of life after PCI with drug-eluting stents or coronary-artery bypass surgery. *New England Journal of Medicine*, **2011**, 364, 1016-26	59.2	181
69	New Anticoagulants in Cardiac Surgery. *Interventional Cardiology Review*, **2011**, 6, 71	4.2	3
68	Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). *EuroIntervention*, **2011**, 7, 670-9	3.1	29
67	What is the evidence allowing us to state that transcatheter aortic valve replacement via the femoral artery is a more attractive option compared to transapical valve replacement?. *EuroIntervention*, **2011**, 7, 903-4	3.1	7
66	Validation of a prognostic model to predict survival after non-small-cell lung cancer surgery. *European Journal of Cardio-thoracic Surgery*, **2010**, 38, 615-9	3	10
65	Editorial comment: Is there enough evidence that proves clinical equipoise between stenting and coronary surgery for patients with left main coronary artery disease?. *European Journal of Cardio-thoracic Surgery*, **2010**, 38, 428-30	3	8
64	Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. *Journal of the American College of Cardiology*, **2010**, 55, 1067-75	15.1	223

63	Long term follow up after surgery in congenitally corrected transposition of the great arteries with a right ventricle in the systemic circulation. *Journal of Cardiothoracic Surgery*, **2010**, 5, 74	1.6	25
62	Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam Study. *American Heart Journal*, **2010**, 159, 323-9	4.9	134
61	Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. *Circulation*, **2010**, 121, 2645-53	16.7	458
60	Bilateral mammary artery vs. single mammary artery grafting: promising early results: but will the match finish with enough players?. *European Heart Journal*, **2010**, 31, 2444-6	9.5	21
59	Two cases of aneurysm of the anterior mitral valve leaflet associated with transcatheter aortic valve endocarditis: a mere coincidence?. *Journal of Thoracic and Cardiovascular Surgery*, **2010**, 140, e36-8	1.5	22
58	Prosthesis-patient mismatch after transcatheter aortic valve implantation with the medtronic CoreValve system in patients with aortic stenosis. *American Journal of Cardiology*, **2010**, 106, 255-60	3	51
57	Transcatheter aortic valve implantation after PARTNER: what is up next?. *EuroIntervention*, **2010**, 6, 560-1	3.1	3
56	Left main stenting: do we need another study?. *EuroIntervention*, **2010**, 6 Suppl J, J118-22	3.1	0
55	Transapical implantation of a self-expanding aortic valve bioprosthesis--animal feasibility study. *European Journal of Cardio-thoracic Surgery*, **2009**, 36, 813-7	3	3
54	How to assess risks of valve surgery: quality, implementation and future of risk models. *Heart*, **2009**, 95, 1958-63	5.1	9
53	Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. *Journal of Thoracic and Cardiovascular Surgery*, **2009**, 137, 881-6, 886e1-5	1.5	136
52	Intraoperative real time three-dimensional transesophageal echocardiographic measurement of hemodynamic, anatomic and functional changes after aortic valve replacement. *Echocardiography*, **2009**, 26, 96-9	1.5	13
51	Complexity of coronary vasculature predicts outcome of surgery for left main disease. *Annals of Thoracic Surgery*, **2009**, 87, 1097-104; discussion 1104-5	2.7	33
50	Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. *New England Journal of Medicine*, **2009**, 360, 961-72	59.2	2778
49	Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement?. *European Journal of Cardio-thoracic Surgery*, **2009**, 35, 953-7; discussion 957	3	37
48	Four-year outcome of OPCAB no-touch with total arterial Y-graft: making the best treatment a daily practice. *Annals of Thoracic Surgery*, **2009**, 88, 796-801	2.7	45
47	Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses. *Annals of Thoracic Surgery*, **2009**, 88, 1814-21	2.7	66
46	The clinical outcome after coronary bypass surgery: a 30-year follow-up study. *European Heart Journal*, **2009**, 30, 453-8	9.5	50

45	Assessment of the SYNTAX score in the Syntax study. *EuroIntervention*, **2009**, 5, 50-6	3.1	367
44	A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis: a two-centre study. *EuroIntervention*, **2009**, 5, 580-8	3.1	44
43	Do we need separate risk stratification models for hospital mortality after heart valve surgery?. *Annals of Thoracic Surgery*, **2008**, 85, 921-30	2.7	48
42	Invited commentary. *Annals of Thoracic Surgery*, **2008**, 86, 219	2.7	
41	Three life-years gained from smoking cessation after coronary artery bypass surgery: a 30-year follow-up study. *American Heart Journal*, **2008**, 156, 473-6	4.9	43
40	Frequency and pattern of de-novo three-vessel and left main coronary artery disease; insights from single center enrolment in the SYNTAX study. *European Journal of Cardio-thoracic Surgery*, **2008**, 34, 376-82; discussion 382-3	3	14
39	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Heart Journal*, **2008**, 29, 1463-70	9.5	533
38	Management of elderly patients with aortic valve disease. *Nature Clinical Practice Cardiovascular Medicine*, **2008**, 5, 600-1		1
37	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Journal of Cardio-thoracic Surgery*, **2008**, 34, 1-8	3	189
36	Optimum management of elderly patients with calcified aortic stenosis. *Expert Review of Cardiovascular Therapy*, **2008**, 6, 491-501	2.5	2
35	Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European association of cardio-thoracic surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). *EuroIntervention*, **2008**, 4, 193-9	3.1	121
34	Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve replacement. *EuroIntervention*, **2008**, 4, 250-5	3.1	39
33	How should I treat a patient with severe and symptomatic aortic stenosis who is rejected for surgical and transfemoral valve replacement and in whom a transapical implantation was aborted? Percutaneous reconstruction of the right ilio-femoral tract with balloon angioplasty followed by the implantation of self-expanding stents. *EuroIntervention*, **2008**, 4, 292-6	3.1	3
32	Early echocardiographic evaluation following percutaneous implantation with the self-expanding CoreValve Revalving System aortic valve bioprosthesis. *EuroIntervention*, **2008**, 4, 351-7	3.1	48
31	Virtual reality 3D echocardiography in the assessment of tricuspid valve function after surgical closure of ventricular septal defect. *Cardiovascular Ultrasound*, **2007**, 5, 8	2.4	11
30	Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. *American Journal of Cardiology*, **2007**, 99, 1072-81	3	224
29	Usefulness of microsimulation to translate valve performance into patient outcome: patient prognosis after aortic valve replacement with the Carpentier-Edwards supra-annular valve. *Journal of Thoracic and Cardiovascular Surgery*, **2007**, 134, 702-9	1.5	10
28	Long-term follow-up and quality of life after closure of ventricular septal defect in adults. *European Journal of Cardio-thoracic Surgery*, **2007**, 32, 215-9	3	27

27	Adapt or die The imperative for a culture of innovation in cardio-thoracic surgical training. *European Journal of Cardio-thoracic Surgery*, **2007**, 31, 959; author reply 960	3	4
26	Allografts for aortic valve or root replacement: insights from an 18-year single-center prospective follow-up study. *European Journal of Cardio-thoracic Surgery*, **2007**, 31, 851-9	3	37
25	Predicted patient outcome after aortic valve replacement with Medtronic Stentless Freestyle bioprostheses. *Journal of Heart Valve Disease*, **2007**, 16, 423-8; discussion 429		6
24	True percutaneous implantation of the CoreValve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar(R) XL and the TandemHeart(R). *EuroIntervention*, **2007**, 2, 500-5	3.1	34
23	Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode. *Journal of Thoracic and Cardiovascular Surgery*, **2006**, 132, 491-8	1.5	53
22	Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. *European Journal of Cardio-thoracic Surgery*, **2006**, 29, 486-91	3	143
21	Does the type of biological valve affect patient outcome?. *Interactive Cardiovascular and Thoracic Surgery*, **2006**, 5, 398-402	1.8	8
20	Emergency surgery due to haematoma in a case of left atrial myxoma. *Heart Lung and Circulation*, **2006**, 15, 191-3	1.8	
19	The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. *American Heart Journal*, **2006**, 151, 1194-204	4.9	239
18	Outcome after aortic valve replacement in young adults: is patient profile more important than prosthesis type?. *Journal of Heart Valve Disease*, **2006**, 15, 479-87; discussion 487		11
17	Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. *Annals of Thoracic Surgery*, **2005**, 79, 375-82	2.7	200
16	Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters. *Annals of Thoracic Surgery*, **2005**, 79, 1137-41	2.7	57
15	Proper treatment selection may improve survival in patients with clinical early-stage nonsmall cell lung cancer. *Annals of Thoracic Surgery*, **2005**, 80, 1021-6	2.7	32
14	Pediatric autograft aortic root replacement: a prospective follow-up study. *Annals of Thoracic Surgery*, **2005**, 80, 1628-33	2.7	23
13	Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. *European Journal of Cardio-thoracic Surgery*, **2005**, 28, 759-62	3	163
12	Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). *Circulation*, **2005**, 111, 1383-9	16.7	273
11	The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. *EuroIntervention*, **2005**, 1, 219-27	3.1	1118
10	Is a bicuspid aortic valve a risk factor for adverse outcome after an autograft procedure?. *Annals of Thoracic Surgery*, **2004**, 77, 1998-2003	2.7	9

9	Long-term follow-up of coronary artery bypass grafting in three-vessel disease using exclusively pedicled bilateral internal thoracic and right gastroepiploic arteries. *Annals of Thoracic Surgery*, **2004**, 77, 794-9; discussion 799	2.7	60
8	Lung resection for non-small-cell lung cancer in patients older than 70: mortality, morbidity, and late survival compared with the general population. *Annals of Thoracic Surgery*, **2003**, 76, 1796-801	2.7	96
7	Factors associated with perioperative complications and long-term results after pulmonary resection for primary carcinoma of the lung. *European Journal of Cardio-thoracic Surgery*, **2003**, 23, 26-9	3	39
6	Value of keeping records of mortality. *The European Journal of Surgery*, **2002**, 168, 436-40		3
5	Echocardiographic imaging of stentless aortic valve prostheses. *Echocardiography*, **2000**, 17, 625-9	1.5	
4	Stentless bioprostheses have ideal haemodynamics, even in the small aortic root. *International Journal of Cardiovascular Imaging*, **2000**, 16, 359-64		3
3	Brom Q three-patch technique for repair of supravalvular aortic stenosis. *Journal of Thoracic and Cardiovascular Surgery*, **1999**, 118, 252-8	1.5	55
2	Survival of proximal third gastric carcinoma. *Journal of Surgical Oncology*, **1998**, 68, 183-6	2.8	5
1	The clinical implications of body surface area as a poor proxy for cardiac output. *Structural Heart*,	0.6	4